Trial Information

Summary: Clinical trial to test a study drug in people who have Tinea Pedis a fungal foot infection

The purpose of this study is to see if the study drug, given for 7 or 14 days, is effective on tinea pedis a fungal foot infection, like athlete’s foot.

Study drug and study procedures will be made available to you at no cost.

To qualify, you must:

  • Be at least 12 years old

You will not qualify if you:

  • Are pregnant or breast-feeding
  • Have used topical antifungal agents within the last 28 days or have taken oral itraconazole and or fluconazole within the last 12 weeks
  • Have has radiation therapy or systemic therapy within the last 6 weeks
  • Have hepatitis B, C or HIV infection
  • Have participated in a clinical drug or device trial within the last 30 days

Contact:

Giselle Singer, Research Coordinator
Biomedical Research Alliance of New York
Mount Sinai School of Medicine
5 East 98th Street, 5th Floor Box 1048
New York, NY 10029
Telephone: 212-241-3288
Email:

Profile Page: Biomedical Research Alliance of New York, New York, NY

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:


Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:37:05 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA